MicroMatrices presented an oral presentation at a recent meeting entitled “Epigenetics in Toxicology and Pathology” held in Newcastle, UK, and hosted jointly by the British Society for  Toxicological Pathology (BSTP) and the British Toxicology Society (BTS). In a talk entitled “Cross species comparison of CAR mediated pro-carcinogenic key events in a 3D liver microtissue model”,…

MicroMatrices are pleased to announce  a new publication entitled  “Cross-species comparison of CAR-mediated procarcinogenic key events in a 3D liver microtissue model”. Published  25 September 2019 in “Toxicology Reports”, the paper describes how our proprietary SpheroMatrices microTMA technology can be used in 3D rat and human liver microtissues to establish key events for CAR Mode of Action…

Five key events* characterize constitutive androstane receptor (CAR) mediated liver carcinogenesis in rats, a process which is not human-relevant. Using SpheroMatrices technology, we have tested whether these events can be detected in 3D rat liver microtissues vs human liver microtissues. We treated rat and human liver microtissues with the prototypical CAR activator phenobarbital (PB)  over…

MicroMatrices are pleased to announce the publication 5 February 2019  of  a paper  entitled “A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine” in  Scientific Reports. This landmark paper describes the application of our proprietary SpheroMatrices microTMA technology in  a heterotypic human glioblastoma model containing normal neuronal cells…

SpheroMatrices is our proprietary technology for creating a tissue microarray from spheroid microtissues, capturing an entire 96 well experiment on a single microscope slide. The microtissues, aligned in two dimensions, can be serially sectioned for  immunostaining and image analysis. Please watch the SpheroMatrices video to learn more: This versatile technology can be applied for:  Model…

    We are pleased to announce the arrival of our new satellite website: www.spheromatrices.com showcasing our spheroid tissue microarray technology for multiplexed 3D cell culture analytics; don’t miss the video!  

Eurotox-SOT debate, San Antonio 2018 Adverse outcome pathways (AOPs) offer potential  for more streamlined and informative risk assessments of new chemical entities. However defining the thousands of permutations of these complex pathways, encompassing  a broad spectrum of molecular targets, is laborious. As discussed in the Eurotox-SOT debate, held at SOT 2018 in San Antonio, the…

MicroMatrices are pleased to announce the  publication  of  a landmark paper  entitled “Dose-dependent effects on rat liver miRNAs 200a/b and 429: potential early biomarkers of liver carcinogenesis”. The paper, published this week in Toxicology Reports,  https://www.sciencedirect.com/science/article/pii/S2214750018300842, describes the identification of early  microRNA biomarkers for receptor mediated rodent hepatocarcingenesis, illustrating the principle that retrospective analyses can…

SpheroMatrices® spheroid tissue microarray (TMA)  platform preserves  the experimental  layout of your 96 well plate making it possible to compare treatment groups within the same experiment . As the TMA sections are fixed, it is possible to perform Heat-induced Epitope Retrieval (HIER) on  the samples without impacting upon the integrity of the tissue. HIER makes…

MicroMatrices supports compound selection in the following ways: SpheroMatrices, a proprietary spheroid tissue microarray technology for de-risking drug safety/efficacy studies. Addressing translatability issues in preclinical drug testing via new analytical processes for profiling 3D organotypic models: spheroids, organoids, PDX 3D models.  Specialist Investigative Toxicology services for risk assessment. Elucidating toxicological/therapeutic mechanisms through the application of…